Faron Pharmaceuticals Oy has announced that it will be hosting a virtual BEXMAB update event to discuss the latest data from the Phase 1 part of the BEXMAB study of Bexmarilimab. The event is scheduled for Tuesday, March 19, and will feature key participants including Dr. Mika Kontro, Dr. Maija Hollmen, and Dr. Juho Jalkanen, along with members of Faron's senior management team.
The focus of the webcast will be on the ongoing BEXMAB trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients, particularly emphasizing the durability of remission and objective responses following treatment with bexmarilimab in combination with standard of care. The event will also include an introduction to myeloid leukemia, insights into bexmarilimab's unique mode of action, and the company's latest understanding of the early and long-term efficacy of bexmarilimab treatment. Additionally, Faron will provide an update on bexmarilimab's future development pathway and business opportunity.
The BEXMAB study is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of AML and MDS. The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC treatment. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function and igniting the immune system.
Faron Pharmaceuticals Ltd. is a global, clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies. Its lead asset, bexmarilimab, is a novel anti-Clever-1 humanized antibody with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. The company's mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.
The webcast will also provide an opportunity for participants to ask questions. Those interested in attending can register for the event on the company's website. For more information, individuals can contact the investor relations team at Faron Pharmaceuticals Oy.